Table 1.
Summary of all cases of MEWDS following Vaccination.
| Study | Age | Race | Gender | Vaccine Type | Time from Vaccination (days) | Laterality | Symptoms | Comorbidities | Presenting VA in affected eye (Snellen) | Vision at Last Visit in Affected Eye | Intervention | Time until Resolution (weeks) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ng et al., 2020 | 33 | Caucasian | M | Influenza (Flucelvax Quadrivalent® Seqirus) |
14 | Right | Paracentral scotomata, Photopsias, Grey haze |
None | 20/20 + 2 | 20/16 | None | 4 |
| Yang et al., 2018 | 33 | Chinese | F | Rabies | 14 | Left | Large paracentral scotoma, Photopsias |
None | 20/20 | 20/20 | Retrobulbar Triamcinolone Acetonide 40 mg | Partially resolved at 8 weeks |
| Abou-Samra et al., 2018 | 27 | Undisclosed | F | Influenza | 14 | Right | Central Photopsias | Stevens-Johnson Syndrome, Wolff-Parkinson-White Syndrome, vesicourethral reflux, mild chronic kidney disease, endometriosis, fibroadenomas, depression with anxiety. |
20/25-2 | undisclosed | None | 8 |
| Ogino et al., 2014 | 16 | Japanese | F | Human Papilloma Virus (Cervarix®, Glaxo Smith Kline) |
14 | Left | Throat pain, Headache, Photopsias, peripheral vision loss |
None | 20/16 | 20/16 | None initially, Betamethasone and anti-histamine later for peripheral vascular leakage and associated visual field constriction | Retinal lesions resolved at two months; worsening peripheral vision loss for 2 years |
| Goyal et al., 2013 | 53 | Caucasian | M | Influenza | 10 | Right | Purple haze | Hepatitis B and C infection, Polysubstance abuse |
20/25-2 | 20/20 | None | 4 |
| Cohen, 2008 | 17 | Undisclosed | F | Human Papilloma Virus and meningococcal | 30 | Left | Photopsias, central and paracentral scotomata | None | 20/200 | 20/20 | None | 8 |
| Stangos et al., 2006 | 50 | Caucasian | F | Hepatitis A and Yellow fever | 10 | Left | Photopsias, paracentral scotomata | None | 20/40 | 20/20 | None | 6 |
| Fine et al., 2001 | 33 | Caucasian | M | Hepatitis A | 13 | Left | Photopsias, Grey haze | None | 20/25-2 | 20/20 | None | 6 |
| Baglivo et al., 1996 | 23 | Undisclosed | F | Hepatitis B booster | 1 | Left | Left Blurred vision, bilateral photopsias | None | 20/200 | Undisclosed -"recovery of vision" | None | 12 |
| n = 9 | Mean: 31.7 Median 33 Range: 16 - 53 |
Caucasian: 44.4% Asian: 22.2% Undisclosed: 33.3% |
M:F ratio 1:2 | Median 14 Mean: 13.3 Range: 1 - 30 |
OD:OS ratio 1:2 | Photopsias: 88.9% Central/Paracental Scotomata: 44.4% Dyschromatopsia: 33.3% |
77.8% None | Mean: 20/38 Median: 20/25-2 Range: 20/16 - 20/200 |
Mean: 20/18.5 Median: 20/20 Range: 20/16 - 20/20 |
77.8% None | Mean: 6.9 Median: 6 Range: 4 - 12 |